Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yu-Yun Shao

Showing results (61-70 of 114) with videos related to

Pageof 12
Sort By:
Expert Review of Gastroenterology & Hepatology|May 29, 2019
Considerations of heterogeneity in clinical trials for hepatocellular carcinomaTsung-Hao Liu, Yu-Yun Shao, Li-Chun Lu, et al.
Heliyon|August 5, 2024
Cyclin dependent kinase 9 inhibition reduced programmed death-ligand 1 expression and improved treatment efficacy in hepatocellular carcinomaYu-Yun Shao, Min-Shu Hsieh, Yi-Hsuan Lee, et al.
Anticancer Research|November 24, 2011
Impact of baseline hepatitis B viral DNA levels on survival of patients with advanced hepatocellular carcinomaYu-Yun Shao, Pei-Jer Chen, Zhong-Zhe Lin, et al.
Journal of Hepatology|September 17, 2013
Prognosis of patients with advanced hepatocellular carcinoma who failed first-line systemic therapyYu-Yun Shao, Chih-Horng Wu, Li-Chun Lu, et al.
BMC Cancer|May 26, 2016
Primary tumor site is a useful predictor of cetuximab efficacy in the third-line or salvage treatment of KRAS wild-type (exon 2 non-mutant) metastatic colorectal cancer: a nationwide cohort studyKuo-Hsing Chen, Yu-Yun Shao, Ho-Min Chen, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|October 6, 2016
Do-not-resuscitate consent signed by patients indicates a more favorable quality of end-of-life care for patients with advanced cancerYi-Hsin Liang, Chih-Hsin Wei, Wen-Hui Hsu, et al.
Thoracic Cancer|June 21, 2023
Different immune contextures underlie tumor site-specific responses to immune checkpoint blockade in esophageal cancerJhe-Cyuan Guo, Chia-Lang Hsu, Min-Shu Hsieh, et al.
Cancers|October 13, 2021
Early Changes in DCE-MRI Biomarkers May Predict Survival Outcomes in Patients with Advanced Hepatocellular Carcinoma after Sorafenib Failure: Two Prospective Phase II TrialsBang-Bin Chen, Zhong-Zhe Lin, Yu-Yun Shao, et al.
Diagnostics (Basel, Switzerland)|August 27, 2021
Dynamic Contrast-Enhanced and Intravoxel Incoherent Motion MRI Biomarkers Are Correlated to Survival Outcome in Advanced Hepatocellular CarcinomaBang-Bin Chen, Yu-Yun Shao, Zhong-Zhe Lin, et al.
Anticancer Research|May 7, 2017
Prescription Patterns of Sorafenib and Outcomes of Patients with Advanced Hepatocellular Carcinoma: A National Population StudyLi-Chun Lu, Pei-Jer Chen, Yi-Chun Yeh, et al.
Pageof 12

Showing results (61-70 of 114) with videos related to

Sort By:
Pageof 12
Expert Review of Gastroenterology & Hepatology|May 29, 2019
Considerations of heterogeneity in clinical trials for hepatocellular carcinomaTsung-Hao Liu, Yu-Yun Shao, Li-Chun Lu, et al.
Heliyon|August 5, 2024
Cyclin dependent kinase 9 inhibition reduced programmed death-ligand 1 expression and improved treatment efficacy in hepatocellular carcinomaYu-Yun Shao, Min-Shu Hsieh, Yi-Hsuan Lee, et al.
Anticancer Research|November 24, 2011
Impact of baseline hepatitis B viral DNA levels on survival of patients with advanced hepatocellular carcinomaYu-Yun Shao, Pei-Jer Chen, Zhong-Zhe Lin, et al.
Journal of Hepatology|September 17, 2013
Prognosis of patients with advanced hepatocellular carcinoma who failed first-line systemic therapyYu-Yun Shao, Chih-Horng Wu, Li-Chun Lu, et al.
BMC Cancer|May 26, 2016
Primary tumor site is a useful predictor of cetuximab efficacy in the third-line or salvage treatment of KRAS wild-type (exon 2 non-mutant) metastatic colorectal cancer: a nationwide cohort studyKuo-Hsing Chen, Yu-Yun Shao, Ho-Min Chen, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|October 6, 2016
Do-not-resuscitate consent signed by patients indicates a more favorable quality of end-of-life care for patients with advanced cancerYi-Hsin Liang, Chih-Hsin Wei, Wen-Hui Hsu, et al.
Thoracic Cancer|June 21, 2023
Different immune contextures underlie tumor site-specific responses to immune checkpoint blockade in esophageal cancerJhe-Cyuan Guo, Chia-Lang Hsu, Min-Shu Hsieh, et al.
Cancers|October 13, 2021
Early Changes in DCE-MRI Biomarkers May Predict Survival Outcomes in Patients with Advanced Hepatocellular Carcinoma after Sorafenib Failure: Two Prospective Phase II TrialsBang-Bin Chen, Zhong-Zhe Lin, Yu-Yun Shao, et al.
Diagnostics (Basel, Switzerland)|August 27, 2021
Dynamic Contrast-Enhanced and Intravoxel Incoherent Motion MRI Biomarkers Are Correlated to Survival Outcome in Advanced Hepatocellular CarcinomaBang-Bin Chen, Yu-Yun Shao, Zhong-Zhe Lin, et al.
Anticancer Research|May 7, 2017
Prescription Patterns of Sorafenib and Outcomes of Patients with Advanced Hepatocellular Carcinoma: A National Population StudyLi-Chun Lu, Pei-Jer Chen, Yi-Chun Yeh, et al.
Pageof 12